Riluzole prodrugs for melanoma and ALS: Design, synthesis, and in vitro metabolic profiling-Reference-Cited by-同舟云学术

Riluzole prodrugs for melanoma and ALS: Design, synthesis, and in vitro metabolic profiling

Published:2012-09 Issue:18 Volume:20 Page:5642-5648
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

McDonnell Mark E.,Vera Matthew D.,Blass Benjamin E.,Pelletier Jeffrey C.,King Richard C.,Fernandez-Metzler Carmen,Smith Garry R.,Wrobel Jay,Chen Suzie,Wall Brian A.,Reitz Allen B.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference31 articles.

1. Glutamate antagonists: Deadly liaisons with cancer

2. Glutamate release promotes growth of malignant gliomas

3. The glutamatergic system outside the CNS and in cancer biology

4. The fibroblast growth factor-2 is not essential for melanoma formation in a transgenic mouse model

5. Glutamate antagonists limit tumor growth

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Troriluzole rescues glutamatergic deficits, amyloid and tau pathology, and synaptic and memory impairments in 3xTg‐AD mice;Journal of Neurochemistry;2024-08-30

2. Troriluzole Rescues Glutamatergic Deficits, Amyloid and Tau Pathology, and Synaptic and Memory Impairments in 3xTg-AD Mice;2024-06-13

3. Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies;European Journal of Medicinal Chemistry;2024-06

4. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

5. Amyotrofik Lateral Skleroz Patofizyolojisi ve Tedavi Yaklaşımları;Hacettepe University Journal of the Faculty of Pharmacy;2023-02-14